[1] Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer:role of synthetic and natural inhibitors[J]. Biochim Biophys Acta, 2014,1845(2):136-154.
[2] Ramgolam VS, Markovic-Plese S. Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis[J]. J Signal Transduct, 2011,2011:635721.
[3] Sharma J, Larkin JR. Therapeutic implication of SOCS1 modulation in the treatment of autoimmunity and cancer[J]. Front Pharmacol, 2019,10:324.
[4] Stark GR, Cheon H, Wang Y. Responses to cytokines and interferons that depend upon JAKs and STATs[J]. Cold Spring Harb Perspect Biol, 2018,10(1):a028555.
[5] Velazquez L, Fellous M, Stark GR, et al. A protein tyrosine kinase in the interferon alpha/beta signaling pathway[J]. Cell, 1992,70(2):313-322.
[6] Haan C, Kreis S, Margue C, et al. Jaks and cytokine receptors-an intimate relationship[J]. Biochem Pharmacol, 2006,72(11):1538-1546.
[7] Braunstein J, Brutsaert S, Olson R, et al. STATs dimerize in the absence of phosphorylation[J]. J Biol Chem, 2003,278(36):34133-34140.
[8] Schindler C, Shuai K, Prezioso VR, et al. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor[J]. Science, 1992,257(5071):809-813.
[9] Liszewski W, Gniadecki R. The role of cytokine deficiencies and cytokine autoantibodies in clinical dermatology[J]. J Eur Acad Dermatol Venereol, 2016,30(3):404-412.
[10] Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis:potent immunoregulators and potential therapeutic targets-an updated view[J]. Mediators Inflamm, 2013,2013:165974.
[11] Inagaki-Ohara K, Kondo T, Ito M, et al. SOCS, inflammation, and cancer[J]. Jakstat, 2013,2(3):e24053.
[12] Kalia V, Sarkar S, Ahmed R. CD8 T-cell memory differentiation during acute and chronic viral infections[J]. Adv Exp Med Biol, 2010,684:79-95.
[13] Zhou L, Chong MM, Littman DR. Plasticity of CD4+T cell lineage differentiation[J]. Immunity, 2009,30(5):646-655.
[14] Diehl S, Anguita J, Hoffmeyer A, et al. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1[J]. Immunity, 2000,13(6):805-815.
[15] Seif F, Khoshmirsafa M, Aazami H, et al. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells[J]. Cell Commun Signal, 2017,15(1):23.
[16] Raphael I, Nalawade S, Eagar TN, et al. T cell subsets and their signature cytokines in auto-immune and inflammatory diseases[J]. Cytokine, 2015,74(1):5-17.
[17] Tanaka K, Ichiyama K, Hashimoto M, et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads[J]. J Immunol, 2008,180(6):3746-3756.
[18] Takahashi R, Nishimoto S, Muto G, et al. SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-{gamma} and IL-17A production[J]. J Exp Med, 2011,208(10):2055-2067.
[19] Takahashi R, Nakatsukasa H, Shiozawa S, et al. SOCS1 is a key molecule that prevents regulatory T cell plasticity under inflammatory conditions[J]. J Immunol, 2017,199(1):149-158.
[20] Yoshimura A, Suzuki M, Sakaguchi R, et al. SOCS, inflammation, and autoimmunity[J]. Frontiers in Immunology, 2012,3:20.
[21] Qin H, Wang L, Feng T, et al. TGF-beta promotes Th17 cell development through inhibition of SOCS3[J]. J Immunol, 2009,183(1):97-105.
[22] Chen Z, Laurence A, Kanno Y, et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells[J]. Proc Natl Acad Sci U S A, 2006,103(21):8137-8142.
[23] Seki Y, Inoue H, Nagata N, et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses[J]. Nat Med, 2003,9(8):1047-1054.
[24] Takatori H, Nakajima H, Kagami S, et al. Stat5a inhibits IL-12-induced Th1 cell differentiation through the induction of suppressor of cytokine signaling 3 expression[J]. J Immunol, 2005,174(7):4105-4112.
[25] Chen M, Zhao J, Ali I, et al. Cytokine signaling protein 3 deficiency in myeloid cells promotes retinal degeneration and angiogenesis through arginase-1 up-regulation in experimental autoimmune uveoretinitis[J]. Am J Pathol, 2018,188(4):1007-1020.
[26] Hernandez-Santos N, Huppler AR, Peterson AC, et al. Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections[J]. Mucosal Immunol, 2013,6(5):900-910.
[27] Shi D, Li D, Yin Q, et al. Silenced suppressor of cytokine signaling 1(SOCS1) enhances the maturation and antifungal immunity of dendritic cells in response to Candida albicans in vitro[J]. Immunol Res, 2015,61(3):206-218.
[28] Shi D, Yang J, Wang Q, et al. SOCS3 ablation enhances DC-derived Th17 immune response against Candida albicans by activating IL-6/STAT3 in vitro[J]. Life Sci, 2019,222:183-194.
[29] Lawn SD, Zumla AI. Tuberculosis[J]. Lancet, 2011,378(9785):57-72.
[30] Ramos-Martinez AG, Valtierra-Alvarado MA, Garcia-Hernandez MH, et al. Variability in the virulence of specific Mycobacterium tuberculosis clinical isolates alters the capacity of human dendritic cells to signal for T cells[J]. Mem Inst Oswaldo Cruz, 2019,114:e190102.
[31] Hanekom WA, Mendillo M, Manca C, et al. Mycobacterium tuberculosis inhibits maturation of human monocyte-derived dendritic cells in vitro[J]. J Infect Dis, 2003,188(2):257-266.
[32] Dulphy N, Herrmann JL, Nigou J, et al. Intermediate maturation of Mycobacterium tuberculosis LAM-activated human dendritic cells[J]. Cell Microbiol, 2007,9(6):1412-1425.
[33] Balboa L, Romero MM, Yokobori N, et al. Mycobacterium tuberculosis impairs dendritic cell response by altering CD1b, DC-SIGN and MR profile[J]. Immunol Cell Biol, 2010,88(7):716-726.
[34] Imai K, Kurita-Ochiai T, Ochiai K. Mycobacterium bovis bacillus calmette-guerin infection promotes SOCS induction and inhibits IFN-gamma-stimulated JAK/STAT signaling in J774 macrophages[J]. FEMS Immunol Med Microbiol, 2003,39(2):173-180.
[35] Vazquez N, Greenwell-Wild T, Rekka S, et al. Mycobacterium avium-induced SOCS contributes to resistance to IFN-gamma-mediated mycobactericidal activity in human macrophages[J]. J Leukoc Biol, 2006,80(5):1136-1144.
[36] Carow B, Ye X, Gavier-Widen D, et al. Silencing suppressor of cytokine signaling-1(SOCS1) in macrophages improves Mycobacterium tuberculosis control in an interferon-gamma (IFN-gamma)-dependent manner[J]. J Biol Chem, 2011,286(30):26873-26887.
[37] Srivastava V, Vashishta M, Gupta S, et al. Suppressors of cytokine signaling inhibit effector T cell responses during Mycobacterium tuberculosis infection[J]. Immunol Cell Biol, 2011,89(7):786-791.
[38] 高荣, 王嘉琪, 任浩. SOCS3参与丙型肝炎病毒感染和治疗的研究进展[J]. 微生物与感染, 2019,14(1):46-51.
[39] Xu G, Yang F, Ding CL, et al. MiR-221 accentuates IFNs anti-HCV effect by downregulating SOCS1 and SOCS3[J]. Virology, 2014,462-463:343-350.
[40] Fenner JE, Starr R, Cornish AL, et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity[J]. Nat Immunol, 2006,7(1):33-39.
[41] Zhu Y, Zheng Y, Mei L, et al. Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adeno-shRNA-SOCS1 virus[J]. Int J Oncol, 2013,43(4):1151-1159.
[42] Wang P, Hou J, Lin L, et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1[J]. J Immunol, 2010,185(10):6226-6233.
[43] Ahmed CM, Dabelic R, Martin JP, et al. Enhancement of antiviral immunity by small molecule antagonist of suppressor of cytokine signaling[J]. J Immunol, 2010,185(2):1103-1113.
[44] Sharma N, Kumawat KL, Rastogi M, et al. Japanese encephalitis virus exploits the micro RNA-432 to regulate the expression of suppressor of cytokine signaling (SOCS) 5[J]. Sci Rep, 2016,6:27685. |
